197 related articles for article (PubMed ID: 21671874)
1. Analgesic potential of TRPV3 antagonists.
Reilly RM; Kym PR
Curr Top Med Chem; 2011; 11(17):2210-5. PubMed ID: 21671874
[TBL] [Abstract][Full Text] [Related]
2. TRPV1 signaling: mechanistic understanding and therapeutic potential.
Xia R; Samad TA; Btesh J; Jiang LH; Kays I; Stjernborg L; Dekker N
Curr Top Med Chem; 2011; 11(17):2180-91. PubMed ID: 21671876
[TBL] [Abstract][Full Text] [Related]
3. TRP channel antagonists for pain--opportunities beyond TRPV1.
Bevan S; Andersson DA
Curr Opin Investig Drugs; 2009 Jul; 10(7):655-63. PubMed ID: 19579171
[TBL] [Abstract][Full Text] [Related]
4. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
Wong GY; Gavva NR
Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
[TBL] [Abstract][Full Text] [Related]
6. Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
Liao C; Liu Y; Liu C; Zhou J; Li H; Wang N; Li J; Liu T; Ghaleb H; Huang W; Qian H
Bioorg Med Chem; 2018 Feb; 26(4):845-854. PubMed ID: 29317149
[TBL] [Abstract][Full Text] [Related]
7. Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management.
Pal M; Angaru S; Kodimuthali A; Dhingra N
Curr Pharm Des; 2009; 15(9):1008-26. PubMed ID: 19275664
[TBL] [Abstract][Full Text] [Related]
8. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
Voight EA; Kort ME
Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
[TBL] [Abstract][Full Text] [Related]
9. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
Westaway SM
J Med Chem; 2007 May; 50(11):2589-96. PubMed ID: 17489570
[No Abstract] [Full Text] [Related]
10. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
Gunthorpe MJ; Chizh BA
Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of three transient receptor potential vanilloid receptor 1 antagonists for early use in human intradermal microdose analgesic studies.
Sjögren E; Halldin MM; Stålberg O; Sundgren-Andersson AK
Eur J Pain; 2018 May; 22(5):889-903. PubMed ID: 29377430
[TBL] [Abstract][Full Text] [Related]
12. Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations?
Szallasi A
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jul; 373(4):273-86. PubMed ID: 16773387
[TBL] [Abstract][Full Text] [Related]
13. TRPV1-Targeted Drugs in Development for Human Pain Conditions.
Iftinca M; Defaye M; Altier C
Drugs; 2021 Jan; 81(1):7-27. PubMed ID: 33165872
[TBL] [Abstract][Full Text] [Related]
14. Discovery of indane propanamides as potent and selective TRPV1 antagonists.
Ahn S; Kim YS; Kim MS; Ann J; Ha H; Yoo YD; Kim YH; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Stockhausen H; Christoph T; Lee J
Bioorg Med Chem Lett; 2020 Feb; 30(3):126838. PubMed ID: 31864799
[TBL] [Abstract][Full Text] [Related]
15. Targeting TRPV1 for pain relief: limits, losers and laurels.
Szallasi A; Sheta M
Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
[TBL] [Abstract][Full Text] [Related]
16. Transient receptor potential channels on sensory nerves.
Eid SR; Cortright DN
Handb Exp Pharmacol; 2009; (194):261-81. PubMed ID: 19655110
[TBL] [Abstract][Full Text] [Related]
17. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.
Cui M; Gosu V; Basith S; Hong S; Choi S
Adv Protein Chem Struct Biol; 2016; 104():81-125. PubMed ID: 27038373
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the TRPV1 channel: current clinical trials and recent patents with focus on neurological conditions.
De Petrocellis L; Moriello AS
Recent Pat CNS Drug Discov; 2013 Dec; 8(3):180-204. PubMed ID: 24330123
[TBL] [Abstract][Full Text] [Related]
19. TRPV1: a therapeutic target for novel analgesic drugs?
Szallasi A; Cruz F; Geppetti P
Trends Mol Med; 2006 Nov; 12(11):545-54. PubMed ID: 16996800
[TBL] [Abstract][Full Text] [Related]
20. Transient receptor potential vanilloid (TRPV) channels: Basal properties and physiological potential.
Sasase T; Fatchiyah F; Ohta T
Gen Physiol Biophys; 2022 May; 41(3):165-190. PubMed ID: 35615999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
